Evidence map›Paper›PMID 40641013›Full record

ArticleCurrent medicinal chemistry2026

Designing of Peptide Vaccine by Investigating Monkeypox Virus Membrane Glycoprotein: An Integrated

Saurav Kumar Mishra, Prerna Priya, Abdul Basit, Nikita Krishna, Shopnil Akash, Turki M Dawoud, Mohammed Bourhia, John J Georrge

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Saurav Kumar MishraDepartment of Bioinformatics, University of North Bengal, Siliguri, 734013, District-Darjeeling, West Bengal, India.
Prerna PriyaDepartment of Botany, Purnea Mahila Mahavidyalaya, Purnia, 854301, Bihar, India.
Abdul BasitSchool of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, 110067, India.
Nikita KrishnaBiochemistry and Structural Biology Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Sector 10, Jankipuram Extension, Lucknow, India.
Shopnil AkashComputational Biology Research Laboratory, Faculty of Allied Health Science, Department of Pharmacy, Daffodil International University, Daffodil smart City, Ashulia, Savar, Dhaka, 1207, Bangladesh.
Turki M DawoudDepartment of Botany and Microbiology, College of Science, King Saud University, P. O. BOX 2455, Riyadh, 11451, Saudi Arabia.
Mohammed BourhiaDepartment of Chemistry and Biochemistry, Faculty of Medicine and Pharmacy, Ibn Zohr University, Laayoune, 70000, Morocco.
John J GeorrgeDepartment of Bioinformatics, University of North Bengal, Siliguri, 734013, District-Darjeeling, West Bengal, India.ORCID 0000-0002-9858-6112

Funding

King Saud University, Riyadh, Saudi Arabia ORF-2025-197
6 · The paper itself

Abstract

backgroundIn 2022, the World Health Organisation (WHO) announced new cases of the developing Monkeypox Virus (MPXV), a zoonotic orthopoxvirus viral infection that mimics smallpox signs. Despite the ongoing infection, no proper medication is available to completely overcome this infection.

aimThe study aims to construct a multi-epitope vaccine targeting Monkeypox Virus (MPXV) membrane glycoprotein to provoke robust immune responses.

objectiveTo construct a potential immuno-dominant epitope vaccine to combat MPXV.

methodsThe target sequence, sourced from the UAE-to-India travel case, was analyzed to identify potential B-cell and T-cell epitopes (MHC-I and MHC-II). Immunodominant epitopes were selected and fused with β-defensin-I and PADRE to increase immunogenicity. The vaccine was modeled, docked with TLR3, and subjected to a 500 ns molecular dynamics simulation for stability analysis. Immune responses and bacterial expression were also evaluated.

resultsThe vaccine, comprising 230 amino acids, demonstrated antigenicity (0.6620), non-allergenicity, and broad population coverage. Selected epitopes included 3 B-cells, 4 MHC-I, and 2 MHC-II, ensuring a potent immunodominant profile. Docking with TLR3 revealed a binding affinity of -17.2 kcal/mol, while simulations confirmed their stability. Cloning (pET28a (+)) and immune response analyses showed a strong immunogenic profile, including elevated IgG1, IgM, and antigen levels, supported by a Codon Adaptation Index (CAI) of 1.0.

conclusionThe proposed multi-epitope vaccine shows promise against MPXV. However, further in vivo and in vitro investigations are essential to confirm its immune efficacy.

Indexed as

Membrane GlycoproteinsMonkeypox virusAmino Acid SequenceAnimalsComputer SimulationEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansImmunoinformaticsMolecular Docking SimulationMolecular Dynamics SimulationProtein Subunit VaccinesVaccines, SubunitEpitopes, B-LymphocyteEpitopes, T-LymphocyteMembrane GlycoproteinsProtein Subunit VaccinesVaccines, SubunitEpitopesimmunoinformaticsmembrane glycoproteinmonkeypoxpeptide vaccinesimulation

Identifiers

PMID40641013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.